Danny Villeneuve was appointed Aardvark's Chief Commercial Officer in May 2025. He brings more than 20 years of commercial leadership experience in the biopharmaceutical industry across U.S. and international markets. Most recently he served as EVP, Chief Commercial Officer of Ironshore Pharmaceuticals, where he led the commercial relaunch of its flagship ADHD product ahead of the company's acquisition by Collegium Pharmaceuticals. Earlier he commercialized products in the ADHD, CNS, diabetes and obesity markets with Orexigen Therapeutics, Shire Pharmaceuticals and Novartis Pharmaceuticals. He earned his Bachelor of Science in Medical Biology at Universite du Quebec.